287 related articles for article (PubMed ID: 24627434)
1. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
3. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
[TBL] [Abstract][Full Text] [Related]
4. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 targeted delivery of
Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
[TBL] [Abstract][Full Text] [Related]
6. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma.
Labadie KP; Lehnert AL; Kenoyer AL; Hamlin DK; Ludwig AD; Utria AF; Daniel SK; Mihailovic TN; Prossnitz A; Orozco JJ; Li Y; Wilbur DS; Miyaoka RS; Park JO
EJNMMI Res; 2023 Apr; 13(1):35. PubMed ID: 37103671
[TBL] [Abstract][Full Text] [Related]
8. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3-Targeted
Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
[TBL] [Abstract][Full Text] [Related]
10. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
11. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
12. The development of a Glypican-3-specific binding peptide using
Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056
[TBL] [Abstract][Full Text] [Related]
14. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.
Park JO; Stephen Z; Sun C; Veiseh O; Kievit FM; Fang C; Leung M; Mok H; Zhang M
Mol Imaging; 2011 Feb; 10(1):69-77. PubMed ID: 21303616
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread.
Marquez BV; Zheleznyak A; Lapi SE
J Nucl Med; 2014 May; 55(5):708-9. PubMed ID: 24665087
[No Abstract] [Full Text] [Related]
17. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma.
Ludwig AD; Labadie KP; Seo YD; Hamlin DK; Nguyen HM; Mahadev VM; Yeung RS; Wilbur DS; Park JO
J Oncol; 2019; 2019():4564707. PubMed ID: 31636665
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and preclinical evaluation of a novel probe [
Mo C; Sun P; Liang H; Chen Z; Wang M; Fu L; Huang S; Tang G
Bioorg Chem; 2024 Jun; 147():107352. PubMed ID: 38640719
[TBL] [Abstract][Full Text] [Related]
20. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
